Systemic delivery of P42 peptide: a new weapon to fight Huntington’s disease
Authors:
- Yoan ArribatYAYoan Arribat
- Yasmina Talmat-AmarYTYasmina Talmat-Amar
- Alexia PaucardAPAlexia Paucard
- Pierre LesportPLPierre Lesport
- Nathalie BonneaudNBNathalie Bonneaud
- Caroline BauerCBCaroline Bauer
- Nicole BecNBNicole Bec
- Marie-Laure ParmentierMPMarie-Laure Parmentier
- Lorraine BenignoLBLorraine Benigno
- Christian LarroqueCLChristian Larroque
- Patrick MaurelPMPatrick Maurel
- Florence MaschatFMFlorence Maschat
Open Access
- 5 August 2014
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 2 (1) , 86
Abstract
In Huntington’s disease (HD), the ratio between normal and mutant Huntingtin (polyQ-hHtt) is crucial in the onset and progression of the disease. As a result, addition of normal Htt was shown to improve polyQ-hHtt-induced defects. Therefore, we recently identified, within human Htt, a 23aa peptide (P42) that prevents aggregation and polyQ-hHtt-induced phenotypes in HD Drosophila model. In this report, we evaluated the therapeutic potential of P42 in a mammalian model of the disease, R6/2 mice. To this end, we developed an original strategy for P42 delivery, combining the properties of the cell penetrating peptide TAT from HIV with a nanostructure-based drug delivery system (Aonys® technology), to form a water-in-oil microemulsion (referred to as NP42T) allowing non-invasive per mucosal buccal/rectal administration of P42. Using MALDI Imaging Mass Spectrometry, we verified the correct targeting of NP42T into the brain, after per mucosal administration. We then evaluated the effects of NP42T in R6/2 mice. We found that P42 (and/or derivatives) are delivered into the brain and target most of the cells, including the neurons of the striatum. Buccal/rectal daily administrations of NP42T microemulsion allowed a clear improvement of behavioural HD-associated defects (foot-clasping, rotarod and body weights), and of several histological markers (aggregation, astrogliosis or ventricular areas) recorded on brain sections. These data demonstrate that NP42T presents an unprecedented protective effect, and highlight a new therapeutic strategy for HD, associating an efficient peptide with a powerful delivery technology.Keywords
This publication has 51 references indexed in Scilit:
- Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington diseaseNature Medicine, 2004
- Mutant Huntingtin Promotes the Fibrillogenesis of Wild-type HuntingtinJournal of Biological Chemistry, 2003
- Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical courseBrain, 2003
- Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesisProceedings of the National Academy of Sciences, 2002
- Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's DiseaseJournal of Neuroscience, 2002
- Protein transduction technologyCurrent Opinion in Biotechnology, 2002
- Wild-Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin In VivoThe American Journal of Human Genetics, 2001
- Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in miceNature Genetics, 2000
- Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display ScreeningJournal of Biological Chemistry, 2000
- Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's DiseaseCell, 2000